Bisphosphonate Complications Including Osteonecrosis of the Jaw
Open Access
- 1 January 2006
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2006 (1), 356-360
- https://doi.org/10.1182/asheducation-2006.1.356
Abstract
Bisphosphonate therapy has been incorporated in the standard management of patients with multiple myeloma–related bony disease. Although their efficacy in reducing skeletal related events is important in the supportive management of the myeloma patient, post-marketing experience with this class of agents, particularly the more potent intravenous agents pamidronate and zoledronic acid, have raised cautionary notes regarding the potential side effects of these agents. The focus of this session is to review the risk factors, incidence, prevention strategies and management of bisphosphonate-related osteonecrosis of the jaw. In addition, pathophysiology, incidence and monitoring for renal dysfunction during chronic therapy with these agents are reviewed.Keywords
This publication has 25 references indexed in Scilit:
- Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatmentThe Lancet Oncology, 2006
- Systematic Review: Bisphosphonates and Osteonecrosis of the JawsAnnals of Internal Medicine, 2006
- Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk FactorsJournal of Clinical Oncology, 2006
- Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With CancerJournal of Oncology Practice, 2006
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.Blood, 2005
- Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 casesJournal of Oral and Maxillofacial Surgery, 2004
- A New Insight into the Formation of Osteolytic Lesions in Multiple MyelomaNew England Journal of Medicine, 2003
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996